Bnp Paribas Issuance (P10K91) Trades

Solvonis Therapeutics PLC (LSE:SVNS) non-executive director-elect Dr Renata Crome talked with Proactive about her appointment to the board and what she brings to the company. Dr Crome has an extensive background in pharmaceutical development, having worked at Roche for 30 years. She played a key role in the development of blockbuster treatments such as bevacizumab and obinutuzumab for cancer, as well as Tamiflu for influenza. Following her time at Roche, she transitioned to board roles across commercial and charity organisations and also lectures in pharmaceutical medicine. Discussing her contributions to Solvonis, Dr Crome highlighted her strategic expertise and experience in central nervous system (CNS) treatments. "I have extensive experience in developing treatments in the central nervous system area, and I know the challenges and some of the solutions," she said. She also emphasised her ability to leverage a strong network of experts to support the company's goals. Dr Crome expressed enthusiasm for Solvonis' innovative pipeline and differentiated treatments, as well as the strength of its leadership team. "It’s a privilege to be invited to join them," she said. For more interviews and updates, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications for future content. #SolvonisTherapeutics #Pharmaceuticals #Biotech #HealthcareInnovation #Leadership #CNSResearch #DrugDevelopment #Investing #Biopharma #ExecutiveLeadership

TNR Gold Corp (TSX-V:TNR, OTC:TRRXF) executive chairman Kirill Klip talked with Proactive's Stephen Gunnion about the company’s latest developments, including a key milestone in its transition to a cash-flow-generating royalty business. Klip highlighted that TNR Gold holds royalties on significant projects, including the Los Azules Copper project and the Mariana Lithium project in Argentina. With Los Azules now applying for Argentina's incentive regime for large investments, he explained that the project could see substantial tax reductions, making it easier to attract the $2.7 billion investment required for construction. Discussing Argentina’s economic reforms under President Javier Milei, Klip noted that the country's policies are encouraging large-scale investment in the mining sector. He also pointed to the environmental permit secured for Los Azules, bringing it closer to a construction decision, with a feasibility study expected in the first half of the year. Klip also shared insights from Fundamental Research Corporation’s latest analysis, which increased its price target for TNR Gold from $0.24 to $0.28, underscoring the company's transition from a project generator to a cash-flow-generating royalty company. Watch the full interview for more insights into TNR Gold’s latest developments. For more interviews like this, subscribe to Proactive’s YouTube channel, give this video a like, and turn on notifications for future updates! #TNRGold #MiningInvesting #LosAzules #CopperMining #LithiumInvesting #MiningStocks #ArgentinaMining #RoyaltyCompany #StockMarket #JavierMilei

Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo talked with Proactive about the company’s strategic collaboration with GATC Health, a leader in artificial intelligence-driven drug discovery. Mazzo explained that GATC’s technology, which is recognized by Lloyd’s of London for clinical trial risk assessment, will be used to analyze Lisata’s lead candidate, certepetide, and identify potential new drug combinations. Mazzo highlighted that this collaboration will optimize Lisata’s ongoing cancer research, including trials in pancreatic ductal adenocarcinoma, cholangiocarcinoma, and other cancers. He noted that GATC’s AI technology can perform billions of simulations rapidly, potentially reducing the cost and risk of drug development. Discussing Lisata’s 2025 outlook, Mazzo described it as a "data-rich year," with upcoming results from the ASCEND trial and other studies. He emphasized the potential for certepetide in combination with immunotherapy and the company’s ongoing discussions with regulatory agencies and potential partners. To watch more interviews like this, visit Proactive’s YouTube channel. Don't forget to like this video, subscribe, and enable notifications for future updates. #LisataTherapeutics #Biotech #CancerResearch #AIinHealthcare #DrugDevelopment #ClinicalTrials #GATCHealth #Pharma #Oncology #Investing

Provaris Energy Ltd (ASX:PV1, OTC:GBBLF) managing director and CEO Martin Carolan talked with Proactive about the company’s latest progress in hydrogen transport and storage solutions. The company has signed a second non-binding memorandum of understanding (MoU) to supply hydrogen from Norway to Germany, aiming for discussions on non-binding term sheets by mid-2025. Carolan emphasised that Provaris is in a "sweet spot" given the industry’s shift towards practical hydrogen projects, with a focus on cost efficiency and scalable delivery. He highlighted that recent developments in Germany reinforce the country’s commitment to hydrogen as a decarbonistion strategy. Additionally, Provaris is advancing its CO2 storage initiative through a joint development with Yinson Production, targeting large-scale liquid CO2 storage solutions. The company also secured the Fiska facility in Norway, which will play a role in testing and validating its H2 Neo carrier technology. Looking ahead, Carolan noted that investors can anticipate key milestones, including binding hydrogen sales agreements and further progress on CO2 storage projects. For more insights from industry leaders, visit Proactive’s YouTube channel, like this video, subscribe, and turn on notifications for future updates. #ProvarisEnergy #Hydrogen #EnergyTransition #Germany #Norway #CO2Storage #RenewableEnergy #SustainableSolutions #HydrogenTransport #GreenEnergy